Brigatinib: Updated Phase II data

Updated data from 112 patients ages >=18 with locally advanced or metastatic ALK-positive NSCLC whose disease has progressed on Xalkori crizotinib in the open-label, international, pivotal Phase II ALTA trial showed that once-daily 90 mg oral brigatinib led to a median PFS of 9.2 months and a 1-year OS rate of 71%. In 110 patients who received once-daily 90 mg brigatinib for 7 days followed by once-daily 180 mg brigatinib, median PFS was 12.9 months and the 1-year OS rate was 80%. Median OS was not reached in either arm. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Ariad previously reported data from the trial (see BioCentury, May 23). ...